ROTFL. It was one patient in an early stage trial, They still need to complete the rest of the Phase II, then Phases III and IV.
Only 4% (19 our of 430) of drugs evaluated for ischemic stroke between 1995-2015. ever reached the market.Acta Pharm Sin B. 2016 Nov; 6(6): 522–530.Published online 2016 Jul 28. doi: 10.1016/j.apsb.2016.06.013PMCID: PMC5071630PMID: 27818918The fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995–2015
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071630/
The reason why the price doesn't move on news is because not everybody is as ignorant about the drug approval process or as wildly overconfident as CUV holders.
Ann: Media release - First stroke patient with afamelanotide, page-10
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.28 |
Change
-0.250(1.85%) |
Mkt cap ! $664.8M | |||
| Open | High | Low | Value | Volume |
| $13.55 | $13.62 | $13.25 | $1.157M | 86.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 227 | $13.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.42 | 228 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| CUV (ASX) Chart |